continued for approximately 6 weeks postoperatively, when it was discontinued in all but 8 patients.
In the follow-up period-mean 16 months (range 8 to 31 months)-there were 4 late deaths, 2 of which were sudden. There was no documented episode of thromboembolism or valve degeneration. All except 2 patients were clinically improved from NYHA class III or IV preoperatively to class I or II postoperatively.
Initial results with Hancock porcine xenograft valves are most satisfactory and compare more than favourably with other commercially available valve substitutes.
The ideal heart valve substitute should be readily available, easily inserted, free from thromboembolic and infectious complications, haemodynamically satisfactory, and durable in the long term.
Dissatisfaction with the thrombogenicity, haemodynamic performance, and long-term durability of many mechanical prostheses (Stanford et al., 1972; Vidne et al., 1973) has led to the increasing use of many different types of tissue valves (Ionescu et al., 1974; Wallace, 1975 In 53 patients in whom coronary artery disease was either excluded by selective coronary angiography or was not suspected, there was 1 death (mortality 1-9%) after a single aortic valve replacement (Table 2) .
In 13 patients, the presence of ischaemic heart disease was proved preoperatively by selective coronary angiography and left ventricular angiography. In 12 of these patients, valve replacement was combined with coronary artery vein bypass grafting without mortality. One patient, submitted to aortic and mitral valve replacement and left ventricular aneurysmectomy without coronary artery grafting, died intraoperatively, giving a hospital mortality for this group of 7-7 per cent ( Table 3) .
The aetiology of the valvular disease in the different patient groups is shown in Tables 4, 5, 7, and 8. Of the 35 patients whose first presentation for cardiac surgery had been with rheumatic mitral valve disease, 20 had already been submitted to a variety of surgical procedures (Table 6 ).
SURGICAL TECHNIQUE
Standard bicaval-aortic route cardiopulmonary bypass, using a disposable bubble oxygenator and roller pump, was employed. Flow rates varied between 2 and 3*5 litres/min with a mean arterial pressure between 40 and 70 mmHg. Mild hypothermia down to 31 'C was reached in most patients.
All operations were performed through a vertical median sternotomy incision. The aorta was crossclamped throughout the intracardiac procedures, the myocardium being protected by continuous irrigation with cold saline solution at 4°C. Horizontal mattress sutures were used to secure all valves and the struts of the mitral and tricuspid prostheses were orientated so as to produce minimal obstruction to ventricular outflow.
Oral anticoagulation with warfarin was started on the first postoperative day and was discontinued after 6 weeks, except in those patients with a previous history of an embolism, left atrial thrombus at: operation, or a giant left atrium.
Results
There were 2 hospital deaths (mortality rate 3%).
One patient with calcific aortic stenosis and mitral regurgitation with coronary artery disease did not have a preoperative left ventricular cineangiogram as the aortic valve could not be crossed. At operation Of 31 patients in class III (NYHA classification) preoperatively, 3 died, 24 improved to class I, and 4 to class II. Thirty-five patients were class IV preoperatively; 25 improved to class I, 6 to class II, and 1 to class III. One patient remained in class IV until death at 20 months and 2 other patients died.
Actuarial survival curves show an overall survival rate of just under 80 per cent at 21 years. Over this period, survival after mitral valve replacement was 80-2 per cent and survival for valve replacement in association with ischaemic heart disease was 84-6 per cent at 36 months. For double valve replacement survival was 85-7 per cent at 2 years, and for single aortic valve replacement survival was 94-5 per cent at 18 months.
Discussion
The results of this study confirm the findings of others (Ionescu et al., 1972; Brown et al., 1974; Carpentier et al., 1974; Horowitz et al., 1974; Stinson et al., 1974; Zuhdi, 1974; Zuhdi et al., 1974; Cohn et al., 1975; Pipkin et al., 1976 ) that the porcine aortic xenograft bioprosthesis (Hancock Laboratories) functions very well as a heart valve substitute in the mitral, aortic, and tricuspid position in man. A particular feature in these patients was the rapid and smooth immediate postoperative recovery that the majority enjoyed and which was attributed to the very favourable haemodynamic characteristics of these valves. Improvement in at least two functional classes was seen in 98 per cent of the surviving patients. Failure to obtain symptomatic improvement was related in one patient to myocardial disease after 3 previous mitral valve procedures, and to non-cardiac causes in another patient with osteoarthritis.
Serious valve-related problems were extremely few. In particular, there was no incidence of valve failure or infection over the first 2j years postoperatively and there was only one probable episode of systemic embolisation. This occurred during the first 6 postoperative weeks while the patient was still on oral anticoagulation, a time when the valve sewing ring is not yet endothelialised and when the risk of systemic embolisation is known to be highest with all prostheses.
After this first 6-week period, anticoagulation with its attendant morbidity and mortality (Stanford et al., 1972; Cleland and Molloy, 1973; Vidne et al., 1973) was avoided in the large majority of patients (87%). It is possible that thrombus formation in the left atrium may have had a part to play in the sudden death of 2 patients comparatively soon after their oral anticoagulation had been discontinued. Because of our experience with these patients, we are now inclined to keep most patients on long-term oral anticoagulation after mitral valve replacement with a Hancock prosthesis if they have more than moderate left atrial enlargement and are in atrial fibrillation, and particularly if there is clot in the left atrium at the time of operation.
The durability of these valves, with not one single valve failure occurring throughout the follow-up period, has been most encouraging and is in striking contrast to the experience with many other earlier forms of tissue valve prosthesis, where there has been a steady attrition rate from the early postoperative period (Wallace, 1975) . This improved durability has been largely attributed to 2 factors.
The use of a flexible stent has been shown to reduce stress at the cusp edges on closure up to 90 per cent (Reis et al., 1971) ; secondly, the glutaraldehyde process used to 'tan' the valve is known to produce much more stable cross-linkage between the collagen fibres of the leaflets than has been achieved with previous preservation methods (Carpentier et al., 1969) .
In our opinion, the Hancock porcine xenograft prosthesis fulfils many of the characteristics of an ideal human valve substitute and compared more than favourably with other commercially available valve substitutes.
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